These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38577458)

  • 1. Assessment of programmed death-ligand 1 expression in primary tumors and paired lymph node metastases of gastric adenocarcinoma.
    Coimbra BC; Pereira MA; Cardili L; Alves VAF; de Mello ES; Ribeiro U; Ramos MFKP
    World J Gastrointest Oncol; 2024 Mar; 16(3):883-893. PubMed ID: 38577458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.
    Gao Y; Li S; Xu D; Chen S; Cai Y; Jiang W; Zhang X; Sun J; Wang K; Chang B; Wang F; Hong M
    Chin J Cancer; 2017 Jul; 36(1):61. PubMed ID: 28754154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer.
    Pereira MA; Ramos MFKP; Dias AR; Ribeiro R; Cardili L; Zilberstein B; Cecconello I; Ribeiro U; de Mello ES; de Castria TB
    Virchows Arch; 2021 Jun; 478(6):1039-1048. PubMed ID: 33098489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
    Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
    BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases.
    Liu DHW; Grabsch HI; Gloor B; Langer R; Dislich B
    J Cancer Res Clin Oncol; 2023 Nov; 149(14):13345-13352. PubMed ID: 37491637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High programmed death-ligand 1 expression is a poor prognostic indicator for esophageal squamous cell carcinoma and is correlated with two-field lymph node metastasis.
    Liang M; Yu F; Wu W; Chen H; Zheng B; Zheng W; Zhu Y; Chen C
    Transl Cancer Res; 2020 Apr; 9(4):2472-2481. PubMed ID: 35117606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?
    Schulz GB; Todorova R; Braunschweig T; Rodler S; Volz Y; Eismann L; Pfitzinger P; Jokisch F; Buchner A; Stief C; Mayr D; Casuscelli J
    Urol Oncol; 2021 Oct; 39(10):734.e1-734.e10. PubMed ID: 34261585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
    Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
    Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Heterogeneity in PD-L1 expression on infiltrating immune cells between the primary and metastatic breast cancers].
    Wang XR; Zhang NN; Lyu F; Wang HL; Liu YP
    Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):430-434. PubMed ID: 32392925
    [No Abstract]   [Full Text] [Related]  

  • 10. Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases.
    Keller MD; Neppl C; Irmak Y; Hall SR; Schmid RA; Langer R; Berezowska S
    Mod Pathol; 2018 Jan; 31(1):101-110. PubMed ID: 28884747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
    Zhang C; Yang Q
    Front Oncol; 2020; 10():572203. PubMed ID: 33634012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary tumor resection for initially staged IV breast cancer: An emphasis on programmed death-ligand 1 expression, promoter methylation status, and survival.
    Erol T; İmamoğlu NE; Aydin B; Taşkiran ZE; Esendağli G; Kösemehmetoğlu K; Baykal A
    Medicine (Baltimore); 2019 Aug; 98(33):e16773. PubMed ID: 31415379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of the programmed death ligand-1 combined positive score in tumors and clinicopathological features in esophageal cancer.
    Huang Z; Jin Y; Cai X; Chen L; Shen X; Li B; Chen H; Li Y
    Thorac Cancer; 2022 Feb; 13(4):523-532. PubMed ID: 34953041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed Death-Ligand 1 (PD-L1) Positivity and Factors Associated with Poor Prognosis in Patients with Gastric Cancer: An Umbrella Meta-Analysis.
    Hassen G; Kasar A; Jain N; Berry S; Dave J; Zouetr M; Priyanka Ganapathiraju VLN; Kurapati T; Oshai S; Saad M; Pathan J; Kamat S; Tirupathi R; Patel UK; Rana RK
    Cureus; 2022 Apr; 14(4):e23845. PubMed ID: 35530821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.
    Wang L; Zhang Q; Ni S; Tan C; Cai X; Huang D; Sheng W
    Cancer Med; 2018 Jun; 7(6):2612-2620. PubMed ID: 29673110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.
    Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K
    World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
    Ma J; Li J; Qian M; Han W; Tian M; Li Z; Wang Z; He S; Wu K
    Diagn Pathol; 2018 Nov; 13(1):91. PubMed ID: 30463584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordance of PD-L1 expression in triple-negative breast cancers in Chinese patients: A retrospective and pathologist-based study.
    Chen C; Ma X; Li Y; Ma J; Yang W; Shui R
    Pathol Res Pract; 2022 Oct; 238():154137. PubMed ID: 36152566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors.
    Zhang L; Qiu M; Jin Y; Ji J; Li B; Wang X; Yan S; Xu R; Yang D
    Int J Clin Exp Pathol; 2015; 8(9):11084-91. PubMed ID: 26617827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer.
    Miyakoshi J; Yazaki S; Shimoi T; Onishi M; Saito A; Kita S; Yamamoto K; Kojima Y; Sumiyoshi-Okuma H; Nishikawa T; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Fujiwara Y; Yoshida M; Yonemori K
    Virchows Arch; 2023 Dec; 483(6):855-863. PubMed ID: 37668667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.